Stereological Study of the Effects of Letrozole and Estradiol Valerate Treatment on the Ovary of Rats

Overview

Journal Clin Exp Reprod Med

Date 2013 Nov 2

PMID 24179868

Citations 22

Authors

Ali Noorafshan

Maryam Ahmadi

Seyed-Fakhroddin Mesbah

Saied Karbalay-Doust

Affiliations

Soon will be listed here.

Abstract

Objective: Letrozole and estradiol valerate are used to treat some hormonally-responsive symptoms and also in modeling of the polycystic ovary syndrome. However, the stereological analysis of the ovary has received less attention. Estimation of the whole ovary volume using the Cavalieri method can be applied in any orientation desired, but estimation of the mean volume of the oocytes requires isotropic uniform random sectioning. Here, a combined method was developed for estimating the parameters. To our knowledge, no comparison has been made of the effects of letrozole and estradiol on the ovary.

Methods: Sixty rats were divided into 4 groups receiving estradiol (4 mg/kg), olive oil, letrozole (1 mg/kg), or normal saline. After 21 days, their ovaries were studied.

Results: Relative to the control group, the total volume of the ovary and the cortex increased in the letrozole-treated and estradiol-treated rats. In addition, the number of the preantral, antral, and granulosa cells decreased by 43% to 56% in the letrozole- and estradiol-treated rats. On average, a 19% increase was observed in the atretic oocytes of the letrozole-treated and estradiol-treated rats, but the mean oocyte volume decreased by 29% to 44% in letrozole- and estradiol-treated rats. Furthermore, the letrozole-treated rats showed a 5-fold and 7-fold increase in the volume of the cysts and corpus luteum, respectively. A 3-fold increase was found in the volume of both the cysts and corpus luteum in the estradiol group.

Conclusion: The structural changes of the ovary were most pronounced in the letrozole-treated animals.

Citing Articles

Histopathological evaluation of infertility: Lessons from laboratory rodents.

Ricken A, Hamed M, Akhigbe R Histol Histopathol. 2023; 39(6):671-690.

PMID: 38088133 DOI: 10.14670/HH-18-684.

Agaricus Subrufescens ameliorates ovarian dysfunction and regulates altered biochemical parameters in rats with Letrozole induced polycystic ovarian syndrome.

Bukke S, Pathange B, Karumanchi S, Marri J, Boyina R, Rachamsetty K J Ovarian Res. 2023; 16(1):221.

PMID: 37993900 PMC: 10664634. DOI: 10.1186/s13048-023-01311-1.

Effect of Formaldehyde and Curcumin on Histomorphological Indices, Gene Expression Associated with Ovarian Follicular Development, and Total Antioxidant to Oxidant Levels in Wistar Rats.

Farshad Z, Shahedi A, Fesahat F, Hassanpour A, Anvari M Int J Biomater. 2023; 2023:4662440.

PMID: 36776151 PMC: 9908331. DOI: 10.1155/2023/4662440.

The effects of melatonin and metformin on histological characteristics of the ovary and uterus in letrozole-induced polycystic ovarian syndrome mice: A stereological study.

Lohrasbi P, Karbalay-Doust S, Tabei S, Azarpira N, Alaee S, Rafiee B Int J Reprod Biomed. 2023; 20(11):973-988.

PMID: 36618831 PMC: 9806248. DOI: 10.18502/ijrm.v20i11.12365.

Thymoquinone improves folliculogenesis, sexual hormones, gene expression of apoptotic markers and antioxidant enzymes in polycystic ovary syndrome rat model.

Alaee S, Mirani M, Derakhshan Z, Koohpeyma F, Bakhtari A Vet Med Sci. 2022; 9(1):290-300.

PMID: 36104839 PMC: 9857009. DOI: 10.1002/vms3.958.

References

Shi D, Vine D . Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Fertil Steril. 2012; 98(1):185-93. DOI: 10.1016/j.fertnstert.2012.04.006. View

Charleston J, Hansen K, Thyer A, Charleston L, Gougeon A, Siebert J . Estimating human ovarian non-growing follicle number: the application of modern stereology techniques to an old problem. Hum Reprod. 2007; 22(8):2103-10. DOI: 10.1093/humrep/dem137. View

Myers M, Britt K, Wreford N, Ebling F, Kerr J . Methods for quantifying follicular numbers within the mouse ovary. Reproduction. 2004; 127(5):569-80. DOI: 10.1530/rep.1.00095. View

Padmanabhan V, Veiga-Lopez A . Animal models of the polycystic ovary syndrome phenotype. Steroids. 2013; 78(8):734-40. PMC: 3700672. DOI: 10.1016/j.steroids.2013.05.004. View

Garzo V, Dorrington J . Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin. Am J Obstet Gynecol. 1984; 148(5):657-62. DOI: 10.1016/0002-9378(84)90769-5. View

Gundersen H, Bendtsen T, Korbo L, Marcussen N, Moller A, Nielsen K . Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 1988; 96(5):379-94. DOI: 10.1111/j.1699-0463.1988.tb05320.x. View

Baravalle C, Salvetti N, Mira G, Pezzone N, Ortega H . Microscopic characterization of follicular structures in letrozole-induced polycystic ovarian syndrome in the rat. Arch Med Res. 2006; 37(7):830-9. DOI: 10.1016/j.arcmed.2006.04.006. View

McCarthy G, Brawer J . Induction of Stein-Leventhal-like polycystic ovaries (PCO) in the rat: a new model for cystic ovarian disease. Anat Rec. 1990; 228(2):137-44. DOI: 10.1002/ar.1092280205. View

Cruz G, Barra R, Gonzalez D, Sotomayor-Zarate R, Lara H . Temporal window in which exposure to estradiol permanently modifies ovarian function causing polycystic ovary morphology in rats. Fertil Steril. 2012; 98(5):1283-90. DOI: 10.1016/j.fertnstert.2012.07.1060. View

10.

Apter D . How possible is the prevention of polycystic ovary syndrome development in adolescent patients with early onset of hyperandrogenism. J Endocrinol Invest. 1998; 21(9):613-7. DOI: 10.1007/BF03350786. View

11.

Gundersen H, Bagger P, Bendtsen T, Evans S, Korbo L, Marcussen N . The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS. 1988; 96(10):857-81. DOI: 10.1111/j.1699-0463.1988.tb00954.x. View

12.

Dhar A, Dockery P, O W, Turner K, Lenton E, Cooke I . The human ovarian granulosa cell: a stereological approach. J Anat. 1996; 188 ( Pt 3):671-6. PMC: 1167495. View

13.

MAHAJAN D . Polycystic ovarian disease: animal models. Endocrinol Metab Clin North Am. 1988; 17(4):705-32. View

14.

Kafali H, Iriadam M, Ozardali I, Demir N . Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res. 2004; 35(2):103-8. DOI: 10.1016/j.arcmed.2003.10.005. View

15.

Bhatnagar A . The discovery and mechanism of action of letrozole. Breast Cancer Res Treat. 2007; 105 Suppl 1:7-17. PMC: 2001216. DOI: 10.1007/s10549-007-9696-3. View

16.

Brawer J, Munoz M, Farookhi R . Development of the polycystic ovarian condition (PCO) in the estradiol valerate-treated rat. Biol Reprod. 1986; 35(3):647-55. DOI: 10.1095/biolreprod35.3.647. View

17.

Karbalay-Doust S, Noorafshan A . Stereological estimation of ovarian oocyte volume, surface area and number: application on mice treated with nandrolone decanoate. Folia Histochem Cytobiol. 2012; 50(2):275-9. DOI: 10.5603/fhc.2012.0037. View

18.

Manneras L, Cajander S, Holmang A, Seleskovic Z, Lystig T, Lonn M . A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007; 148(8):3781-91. DOI: 10.1210/en.2007-0168. View